Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario. In systemic sclerosis (SSc), there is no proven treatment to prevent disease progression. In a recent meta-analysis of three randomised controlled trials (RCTs) and six open prospective studies on cyclophosphamide (CYC), no significant changes in lung function were observed. Further RCTs on early SSc are needed to assess the real efficacy of CYC in inducing remission and increasing survival. I. Miniati. Arthritis Research & Therapy 23 January 2009 (Also see: Cytoxan and Pulmonary Fibrosis)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Cyclophosphamide in systemic sclerosis
No replies to this topic